Adaptive platform trial for new dengue treatments
Treatments studied
Part of Infections clinical trials.
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dengue confirmed by a rapid test (NS1 positive).
- You have had fever for less than 48 hours when you start the trial.
- You are at least 10 years old (or older, depending on the drug being tested).
- You agree to stay in the hospital for about 5 days and return for check-ups at day 30 and day 60.
- You do not have severe dengue symptoms like shock, heavy bleeding, or organ failure at the start.
- You are not pregnant, breastfeeding, or have other serious health conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new medicines for people hospitalized with moderate-to-severe dengue fever. Dengue is a mosquito-borne virus that can cause serious complications like severe bleeding, organ damage, or shock. The trial aims to find treatments that help patients recover faster and avoid life-threatening complications.
This trial tests a new experimental drug, EYU688, for adults with dengue fever. It aims to see if the drug is safe and effective. You may qualify if you have early dengue symptoms, have tested positive for dengue, and are otherwise healthy.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
This study tests a controlled dengue infection in people who already have immunity to some types of dengue. It aims to understand how the immune system responds and to help develop better vaccines. You may qualify if you are a healthy adult aged 18-40 and have evidence of prior dengue exposure to certain virus types.
This trial tests whether a new medicine called CP-COV03 can help people recover faster from dengue fever or dengue-like illness. You would receive either the study medicine or a placebo (inactive pill) and be monitored closely to see if symptoms improve.
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
Hear when a new Dengue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.